Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | EDNRB | P24530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL967161 | 0.78 | POLB (0.48) | POLBLMNAKDM4ETDP1APEX1 | |
| SCHEMBL4069733 | 0.76 | POLB (0.39) | POLBLMNAKDM4ETDP1APEX1 | |
| SCHEMBL16756317 | 0.76 | POLB (0.39) | POLBLMNAKDM4ETDP1APEX1 | |
| SCHEMBL3464997 | 0.76 | POLB (0.39) | POLBLMNAKDM4ETDP1APEX1 | |
| SCHEMBL4982390 | 0.75 | KDM4E (0.36) | POLBLMNAKDM4ETDP1APEX1 | |
| SCHEMBL4515462 | 0.74 | — | — | |
| SCHEMBL7648990 | 0.74 | — | — | |
| SCHEMBL8349202 | 0.74 | — | — | |
| SCHEMBL29953921 | 0.73 | — | — | |
| SCHEMBL12226905 | 0.72 | POLB (0.48) | POLBLMNAKDM4ETDP1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3258929-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2022-04-27 | — | — | EP | disclosed |
| US-10351558-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180022747-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-01-25 | — | — | US | disclosed |
| EP-3258929-A1 | FACTOR IXa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-12-27 | — | — | EP | disclosed |
| WO-2016133793-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20080004293-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC. | 2008-01-03 | — | — | US | disclosed |
| EP-1775297-A2 | Adenosine receptor antagonists and methods of making and using the same | Biogen Idec MA, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1230241-B1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20050222179-A1 | Adenosine receptor antagonists and methods of making and using the same | ENSINGER CAROL L | 2005-10-06 | — | — | US | disclosed |
| US-20030225038-A1 | Adenosine receptor antagonists and methods of making and using the same | BIOGEN, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6605600-B1 | Diuretics | BIOGEN, INCORPORATED | 2003-08-12 | — | — | US | disclosed |
| EP-1230241-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034604-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222179-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | POLB 4082/4885LMNA 1326/4885KDM4E 3832/4885 |
| US-20180022747-A1 | Factor IXa Inhibitors | F9, TFPI, F12 | POLB 3869/4885LMNA 1124/4885KDM4E 3477/4885 |
| US-20030225038-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | POLB 3821/4885LMNA 1572/4885KDM4E 3622/4885 |
| US-10351558-B2 | Factor IXa inhibitors | F9, TFPI, F12 | POLB 3869/4885LMNA 1124/4885KDM4E 3477/4885 |
| US-20080004293-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | ADORA1, ADORA2A, ADORA3 | POLB 4082/4885LMNA 1326/4885KDM4E 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.